Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Active Biotech on real estate transaction
Mandate

Vinge advises Active Biotech on real estate transaction

March 14, 2019 M&A

Active Biotech AB (publ) has entered an agreement regarding sale of the property Forskaren 1 in Lund, to an investor collective led by the real estate company Estea AB. The purchase price amounts to SEK 275 million. The transaction is subject to the general meeting’s approval. 

Vinge advises Active Biotech. Vinge’s team is primarily composed of Erik Sjöman, Anna Edström, Christian Lindhé and Jessica Salomonsson. 

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

 Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025